The other brain: From dementia to schizophrenia, how new discoveries about the brain are revolutionizing medicine and science

Por Heneka, Michael T.
Publicado em 2010

Macrophages derived from infiltrating monocytes mediate autoimmune myelin destruction

Por Heneka, Michael T.
Publicado em 2014

Inflammasome activation and innate immunity in Alzheimer's disease

Por Heneka, Michael T.
Publicado no Brain Pathol (2017)

Microglia in Alzheimer’s disease

Por Sarlus, Heela, Heneka, Michael T.
Publicado no J Clin Invest (2017)

Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration

Por Ising, Christina, Heneka, Michael T.
Publicado no Cell Death Dis (2018)

Microglia in Alzheimer’s disease: Local heroes!

Por Villacampa, Nàdia, Heneka, Michael T.
Publicado no J Exp Med (2020)

PPARs in Alzheimer's Disease

Por Kummer, Markus P., Heneka, Michael T.
Publicado em 2008

Truncated and modified amyloid-beta species

Por Kummer, Markus P, Heneka, Michael T
Publicado em 2014

Screening for Niemann-Pick Type C Disease in a Memory Clinic Cohort

Por Traschütz, Andreas, Heneka, Michael Thomas
Publicado no JIMD Rep (2018)

Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors

Por Tatenhorst, Lars, Hahnen, Eric, Heneka, Michael T.
Publicado em 2008

Role of neuroinflammation in neurodegeneration: new insights

Por McManus, Róisín M., Heneka, Michael T.
Publicado no Alzheimers Res Ther (2017)

Personalized genetics of the cholinergic blockade of neuroinflammation

Por Simchovitz, Alon, Heneka, Michael T., Soreq, Hermona
Publicado no J Neurochem (2017)

Peroxisome Proliferator-Activated Receptor-γ Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell DeathIn Vivo

Por Heneka, Michael T., Klockgether, Thomas, Feinstein, Douglas L.
Publicado no J Neurosci (2000)

PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease

Por Landreth, Gary, Jiang, Qingguang, Mandrekar, Shweta, Heneka, Michael
Publicado em 2008

Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview

Por Brosseron, Frederic, Krauthausen, Marius, Kummer, Markus, Heneka, Michael T.
Publicado em 2014

Time course of dementia following sepsis in German health claims data

Por Fritze, Thomas, Doblhammer, Gabriele, Widmann, Catherine N., Heneka, Michael T.
Publicado no Neurol Neuroimmunol Neuroinflamm (2020)

Impact and Therapeutic Potential of PPARs in Alzheimer's Disease

Por Heneka, Michael T, Reyes-Irisarri, Elisabet, Hüll, Michael, Kummer, Markus P
Publicado em 2011

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

Por Heneka, Michael T., Golenbock, Douglas, Latz, Eicke, Morgan, Dave, Brown, Robert
Publicado no Alzheimers Res Ther (2020)

Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients

Por Okroglic, Sandra, Widmann, Catherine N., Urbach, Horst, Scheltens, Philip, Heneka, Michael T.
Publicado em 2013

CXCR3 modulates glial accumulation and activation in cuprizone-induced demyelination of the central nervous system

Por Krauthausen, Marius, Saxe, Simon, Zimmermann, Julian, Emrich, Michael, Heneka, Michael T, Müller, Marcus
Publicado em 2014